Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation
Source: MDLinx, March 2021
In the present study, the researchers ascertained if circulating tumor cells (CTCs) have potential as biomarkers by checking the number of CTCs, as well as the BRAF genotype of individual CTCs, in melanoma patients undergoing BRAF/MEK inhibitor treatment. In fifteen patients with stage 0–III melanoma, the numbers of CTCs were analyzed.
